JKB-133

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameJKB-133
Drug Alias NameTJC-0133JKB-133
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionToll like receptor 4 antagonists
TargetsToll like receptor 4
Therapy Area/IndicationsHepatitis, AutoimmuneMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTaiwanj Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaiwanj Pharmaceuticals Co LtdHengyi Biomedical Technology (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis, AutoimmuneMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A